Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease

被引：35

作者：

Thaisrivongs, David K. ^{[1
]}

Miller, Steven P. ^{[1
]}

Molinaro, Carmela ^{[1
]}

Chen, Qinghao ^{[1
]}

Song, Zhiguo J. ^{[1
]}

Tan, Lushi ^{[1
]}

Chen, Lu ^{[3
]}

Chen, Wenyong ^{[1
]}

Lekhal, Azzeddine ^{[2
]}

Pulicare, Sarah K. ^{[2
]}

Xu, Yanke ^{[2
]}

机构：

[1] Merck Res Labs, Proc Chem, POB 2000, Rahway, NJ 07065 USA

[2] Merck Res Labs, Chem Engn Res & Dev, Proc Res & Dev, POB 2000, Rahway, NJ 07065 USA

[3] WuXi AppTec Shanghai Pharmaceut Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China

来源：

ORGANIC LETTERS | 2016年 / 18卷 / 22期

关键词：

EFFICIENT COPPER CATALYST; ARYL HALIDES; AMIDATION; AMINES;

D O I：

10.1021/acs.orglett.6b01793

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Verubecestat is an inhibitor of beta-secretase being evaluated for the treatment of Alzheimer's disease. The first generation route relies on an amide coupling with a functionalized aniline, the preparation of which introduces synthetic inefficiencies. The second-generation route replaces this with a copper-catalyzed C-N coupling, allowing for more direct access to the target. Other features of the new route include a diastereoselective Mannich-type addition into an Ellman sulfinyl ketimine and a late-stage guanidinylation.

引用

页码：5780 / 5783

页数：4

共 50 条

[1] APECS TRIAL OF THE BACE1 INHIBITOR VERUBECESTAT FOR PRODROMAL ALZHEIMER'S DISEASE.
不详
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (04): : S1 - S196
[2] A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931)
Thaisrivongs, David A.
Morris, William J.
Tan, Lushi
Song, Zhiguo J.
Lyons, Thomas W.
Waldman, Jacob H.
Naber, John R.
Chen, Wenyong
Chen, Lu
Zhang, Baoyun
Yang, Jun
ORGANIC LETTERS, 2018, 20 (06) : 1568 - 1571
[3] The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
Kennedy, Matthew E.
Stamford, Andrew W.
Chen, Xia
Cox, Kathleen
Cumming, Jared N.
Dockendorf, Marissa F.
Egan, Michael
Ereshefsky, Larry
Hodgson, Robert A.
Hyde, Lynn A.
Jhee, Stanford
Kleijn, Huub J.
Kuvelkar, Reshma
Li, Wei
Mattson, Britta A.
Mei, Hong
Palcza, John
Scott, Jack D.
Tanen, Michael
Troyer, Matthew D.
Tseng, Jack L.
Stone, Julie A.
Parker, Eric M.
Forman, Mark S.
SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (363)
[4] BACE1 in Alzheimer's disease
Sathya, M.
Premkumar, P.
Karthick, C.
Moorthi, P.
Jayachandran, K. S.
Anusuyadevi, M.
CLINICA CHIMICA ACTA, 2012, 414 : 171 - 178
[5] BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Robert Vassar
Alzheimer's Research & Therapy, 6
[6] The potential for BACE1 inhibitors in the treatment of Alzheimer's disease
Hussain, I
IDRUGS, 2004, 7 (07) : 653 - 658
[7] BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
Vassar, Robert
ALZHEIMERS RESEARCH & THERAPY, 2014, 6
[8] BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
Ghosh, Arun K.
Osswald, Heather L.
CHEMICAL SOCIETY REVIEWS, 2014, 43 (19) : 6765 - 6813
[9] Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Coimbra, Judite R. M.
Marques, Daniela F. F.
Baptista, Salete J.
Pereira, Claudia M. F.
Moreira, Paula I.
Dinis, Teresa C. P.
Santos, Armanda E.
Salvador, Jorge A. R.
FRONTIERS IN CHEMISTRY, 2018, 6
[10] Quantification and pharmacokinetic property of verubecestat an BACE1 inhibitor in rat plasma
Wang, Qiong
Wang, Haiyun
Zhong, Youyan
Mei, Yibin
BIOMEDICAL CHROMATOGRAPHY, 2020, 34 (02)

← 1 2 3 4 5 →